#1 Clinical Trials Search in Europe by CTIN

Our offer Newsroom

Find a treatment: By disease

Search all trials

Find therapies in clinical trials near you – page 6

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 962
countries: 28
conditions: 2 101

3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today

Quick filters

Colon cancer+3

Not yet recruiting

Registered drugNo placebo

Effect of a multidisciplinary care pathway on safety of oral anticancer therapy in patients aged ≥70 with cancer (capecitabine and drug combination)

Registered drugNo placebo

France

Participants:65+ years
Substances:Abemaciclib

Contact Research Centre

Plasma cell myeloma

Not yet recruiting

Registered drugNo placebo

Phase 3 study comparing linvoseltamab and daratumumab in high‑risk smoldering multiple myeloma patients

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Daratumumab

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not yet recruiting

Registered drugNo placebo

Study of Camizestrant and Abemaciclib in Patients with ER‑positive HER2‑negative Metastatic Breast Cancer Who Show Rising ctDNA

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Abemaciclib

Contact Research Centre

Pancreatic neuroendocrine tumour

Not yet recruiting

Registered drugNo placebo

Randomized phase III adjuvant capecitabine plus temozolomide versus surveillance in patients with resected stage I‑III pancreatic neuroendocrine tumors

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Capecitabine

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not yet recruiting

Registered drugNo placebo

Study evaluating the omission of exemestane, letrozole, anastrozole, and tamoxifen in postmenopausal women with low-risk early breast cancer.

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Anastrozole

Contact Research Centre

Breast cancer metastatic

Not yet recruiting

Registered drugNo placebo

Study of tucatinib and trastuzumab for patients with HER3-mutant and HER2-not amplified metastatic breast cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Trastuzumab

Contact Research Centre

Febrile neutropenia

Not yet recruiting

Registered drugNo placebo

Comparing amoxicillin-clavulanate alone versus amoxicillin-clavulanate with ciprofloxacin for treating chemotherapy-induced fever in adult hematology patients

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Amoxicillin Sodium

Contact Research Centre

Prostate cancer+1

Not yet recruiting

Registered drug

Study on Darolutamide, Triptorelin, and Leuprorelin Acetate for Patients with Newly Diagnosed Prostate Cancer and Pelvic Lymph Node Metastases

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Darolutamide

Contact Research Centre

Pneumonia

Not yet recruiting

Registered drugNo placebo

Study of antibiotic combination therapy duration based on patient response for adults with community-acquired pneumonia

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Amoxicillin Sodium

Contact Research Centre

Ductal adenocarcinoma of pancreas

Not yet recruiting

Registered drugNo placebo

Study on Maintenance Therapy with OSE2101 and FOLFIRI for Patients with Advanced Pancreatic Cancer After Initial FOLFIRINOX Treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Fluorouracil

Contact Research Centre

Plasma cell myeloma

Not yet recruiting

Registered drugNo placebo

Study on Multiple Myeloma Treatment with Isatuximab, Lenalidomide, and Carfilzomib for Patients Under 66 Eligible for Stem Cell Transplant

Registered drugNo placebo

France

Participants:18–64 years
Substances:Carfilzomib

Contact Research Centre

Triple negative breast cancer

Not yet recruiting

InvestigationalNo placebo

Study on Early Detection of Triple-Negative Breast Cancer Relapse Using [68Ga]Ga-FAPI-46 for Patients at High Risk

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate

Contact Research Centre

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.